NCT06922448View on ClinicalTrials.gov

Study of BLU-808 in Allergic Rhinoconjunctivitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Allergic Rhinoconjunctivitis
Interventions
DRUG

BLU-808

BLU-808 tablets

DRUG

Placebo

Placebo tablets

Trial Locations (1)

ON K1H E4

RECRUITING

Red Maple Trials, Ottawa

Sponsors
All Listed Sponsors
lead

Blueprint Medicines Corporation

INDUSTRY